|
Pronunciation |
|
(eye
oh doe KWIN
ole) |
|
|
U.S. Brand
Names |
|
Yodoxin® |
|
|
Generic
Available |
|
No |
|
|
Canadian Brand
Names |
|
Diodoquin® |
|
|
Synonyms |
|
Diiodohydroxyquin |
|
|
Pharmacological Index |
|
Amebicide |
|
|
Use |
|
Treatment of acute and chronic intestinal amebiasis; asymptomatic cyst
passers; Blastocystis hominis infections; ineffective for amebic
hepatitis or hepatic abscess |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Known hypersensitivity to iodine or iodoquinol; hepatic damage; pre-existing
optic neuropathy |
|
|
Warnings/Precautions |
|
Optic neuritis, optic atrophy, and peripheral neuropathy have occurred
following prolonged use; avoid long-term therapy |
|
|
Adverse
Reactions |
|
>10%: Gastrointestinal: Diarrhea, nausea, vomiting, stomach pain
1% to 10%:
Central nervous system: Fever, chills, agitation, retrograde amnesia,
headache
Dermatologic: Rash, urticaria
Endocrine & metabolic: Thyroid gland enlargement
Neuromuscular & skeletal: Peripheral neuropathy, weakness
Ocular: Optic neuritis, optic atrophy, visual impairment
Miscellaneous: Itching of rectal area |
|
|
Overdosage/Toxicology |
|
Chronic overdose can result in vomiting, diarrhea, abdominal pain, metallic
taste, paresthesias, paraplegia, and loss of vision; can lead to destruction of
the long fibers of the spinal cord and optic nerve
Acute overdose: Delirium, stupor, coma, amnesia
Following GI decontamination, treatment is symptomatic |
|
|
Drug
Interactions |
|
No data reported |
|
|
Mechanism of
Action |
|
Contact amebicide that works in the lumen of the intestine by an unknown
mechanism |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Oral: Poor and irregular
Metabolism: In the liver
Elimination: High percentage of the dose excreted in feces
|
|
|
Usual Dosage |
|
Oral:
Adults: 650 mg 3 times/day after meals for 20 days; not to exceed 1.95 g/day
|
|
|
Dietary
Considerations |
|
Should be administered after meals |
|
|
Monitoring
Parameters |
|
Ophthalmologic exam |
|
|
Test
Interactions |
|
May increase protein-bound serum iodine concentrations reflecting a decrease
in 131I uptake; false-positive ferric chloride test for
phenylketonuria |
|
|
Mental Health: Effects
on Mental Status |
|
May cause agitation or amnesia |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Take as directed; complete full course of therapy. Maintain adequate
hydration (2-3 L/day of fluids unless instructed to restrict fluid intake) and
nutrition. If GI upset occurs, small frequent meals, frequent mouth care,
sucking lozenges, or chewing gum may help. Report unresolved or severe nausea or
vomiting, skin rash, fever, or fatigue. Pregnancy/breast-feeding
precautions: Inform prescriber if you are or intend to be pregnant. Consult
prescriber if breast-feeding. |
|
|
Nursing
Implications |
|
Tablets may be crushed and mixed with applesauce or chocolate
syrup |
|
|
Dosage Forms |
|
Powder: 25 g
Tablet: 210 mg, 650 mg |
|
|
References |
|
"Drugs for Parasitic Infections," Med Lett Drugs Ther, 1993,
35(911):111-22. |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|